Price A H, Fletcher M
ADIS Drug Information Services, Chester, United Kingdom.
Drugs. 1990;40 Suppl 5:1-11. doi: 10.2165/00003495-199000405-00003.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used and therapeutically effective groups of drugs in the Western world. However, gastrointestinal problems constitute all too frequently reported unwanted effects of NSAIDs; their effects on the gastric (and intestinal) mucosa are, therefore, well documented. A review of the evidence suggests that NSAID-induced gastric damage occurs as a result of a dual insult, by NSAID-mediated direct (and indirect) acidic damage followed almost simultaneously by the deleterious (systemic) effect of prostaglandin inhibition. A number of strategies have been used in the management of NSAID-induced gastric damage; however, not all have been entirely successful. Nonetheless, a number of approaches have met with a considerable amount of success, including direct gastroprotection, enhancement of mucosal defence mechanisms and, perhaps most encouragingly, the development of newer NSAIDs which display not only considerable clinical efficacy but a reduced gastrointestinal adverse event profile.
非甾体抗炎药(NSAIDs)是西方世界最常用且治疗有效的药物类别之一。然而,胃肠道问题是NSAIDs极为常见的不良反应;因此,它们对胃(和肠)黏膜的影响已有充分记录。对现有证据的回顾表明,NSAID引起的胃损伤是双重损害的结果,先是NSAID介导的直接(和间接)酸性损伤,几乎同时紧接着是前列腺素抑制产生的有害(全身性)效应。在NSAID引起的胃损伤管理中已采用了多种策略;然而,并非所有策略都完全成功。尽管如此,一些方法已取得了相当大的成功,包括直接胃保护、增强黏膜防御机制,或许最令人鼓舞的是,开发出了不仅具有显著临床疗效而且胃肠道不良事件较少的新型NSAIDs。